Increase in bicycloprostaglandin E2 metabolite in congestive heart failure in response to captopril

Increase in bicycloprostaglandin E2 metabolite in congestive heart failure in response to captopril

Vasodilating prostaglandins may be increased in patients with chronic congestive heart failure (CHF) to balance out the effects of vasoconstricting forces. Significant increases in plasma levels of bicycloprostaglandin E2 metabolite (PGEm), a chemically stable degradation product of the vasodilating...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cardiology (Mahwah, N.J.) N.J.), 1989-02, Vol.12 (2), p.97-101
Hauptverfasser: Stanek, B., Punzengruber, C., Silberbauer, K.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Biological and medical sciences
captopril
Captopril - pharmacology
Captopril - therapeutic use
Cardiovascular system
congestive heart failure
Dinoprostone - analogs & derivatives
Dinoprostone - blood
Heart Failure - blood
Heart Failure - drug therapy
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
prostaglandins
Vasodilator agents. Cerebral vasodilators
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vasodilating prostaglandins may be increased in patients with chronic congestive heart failure (CHF) to balance out the effects of vasoconstricting forces. Significant increases in plasma levels of bicycloprostaglandin E2 metabolite (PGEm), a chemically stable degradation product of the vasodilating prostaglandin E2, were found in response to captopril (39.4±7.8 vs. 46.2±8.2 pg/ml; p
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.4960120206